StockNews.AI
HROW
StockNews.AI
148 days

Harrow Announces Transitional Pass-Through Reimbursement Status for TRIESENCE® (Triamcinolone Acetonide Injectable Suspension) 40 mg/mL

1. Harrow’s TRIESENCE® receives CMS approval for transitional pass-through payment. 2. This approval may enhance revenue potential for HROW's eyecare products.

2m saved
Insight
Article

FAQ

Why Bullish?

The CMS approval for TRIESENCE® is likely to boost sales and profitability, similar to past positive FDA approvals that led to increased stock performance.

How important is it?

The approval directly influences HROW's product offering and revenue stream, making it crucial for the company's future performance.

Why Long Term?

As CMS approval often leads to greater market adoption over time, HROW may see sustained growth in revenue from TRIESENCE®.

Related Companies

VRTXPFEABBV
NASHVILLE, Tenn.--(BUSINESS WIRE)---- $HROW--Harrow (Nasdaq: HROW), a leading North American eyecare pharmaceutical company, today announced that the Centers for Medicare & Medicaid Services (CMS) has approved Harrow's transitional pass-through application for TRIESENCE® (triamcinolone acetonide injectable suspension) 40 mg/mL, a preservative-free synthetic corticosteroid that is approved by the U.S. Food and Drug Administration (FDA) for visualization during vitrectomy and for the treatment of ocula.

Related News